Alkali Metal Or Alkaline Earth Containing Patents (Class 424/722)
-
Publication number: 20090074890Abstract: Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, migraine, headache pain, migraine headache, epilepsy, irritable bowel syndrome, diabetic neuropathy, multiple sclerosis, manic depression and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.Type: ApplicationFiled: November 5, 2004Publication date: March 19, 2009Inventors: Min K. Park, Prasun K. Chakravarty, Bishan Zhou, Edward Gonzalez, Hyun Ok, Brenda Palucki, William H. Parsons, Rosemary Sisco, Michael H. Fisher, Louis L. Zuegner, III
-
Publication number: 20090068290Abstract: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.Type: ApplicationFiled: August 30, 2007Publication date: March 12, 2009Inventors: Michel Bourin, Daniel E. Casey, Steven G. Potkin, Mark Rapaport, John Newcomer, Paul P. Yeung, Sangeeta Raje, Jeff Paul, Saeed Ahmed, Luigi M. Barbato, Nathan A. Shapira, Roseline Pardue, Antje A. Winsemius, Michiel H. de Vries, Marc Debelle, Jens Heisterberg, Mette Krog Josiassen, Jette Buch Ostergard, Dorte Malling, Ellen B. Christensen
-
Publication number: 20090053329Abstract: Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.Type: ApplicationFiled: March 19, 2008Publication date: February 26, 2009Applicant: Acadia Pharmaceuticals, Inc.Inventors: Perry Peters, David Furlano, Daun Bahr, Daniel Van Kammen, Mark Brann
-
Patent number: 7494670Abstract: This invention comprises a composition and the process of using the composition for removing and preventing mold, mildew, and fungal growth. The composition comprises at least one alkali metal perborate, at least one inhibiting compound selected from the group consisting of alkali metal silicates, triazoles and mixtures thereof in any ratio, at least one corrosion inhibitor, and effective amounts of surfactant.Type: GrantFiled: June 10, 2005Date of Patent: February 24, 2009Assignee: United States of America as represented by the Secretary of the NavyInventors: El Sayed S. Arafat, Craig A. Matzdorf, Stephen J. Spadafora, David L. Gauntt, Paul R. Roser, James A. Whitfield
-
Publication number: 20090047334Abstract: The present invention relates to a method for delivery of calcium that avoids the problems with orally given calcium tablets. Particularly, the present invention is a transdermal patch for providing between 40 mg and 500 mg of bioavailable calcium to a patient.Type: ApplicationFiled: August 12, 2008Publication date: February 19, 2009Inventor: Patricia Williams
-
Publication number: 20090041862Abstract: The present invention provides a method for diagnosing a disease or disorder associated with aberrant GSK-3? expression and/or activity or for determining the predisposition of a subject to the disease or disorder. In particular, the methods of the present invention comprise detecting a marker that comprises one or more polymorphisms and/or one or more allelic variants of a glycogen synthase kinase 3? gene. The present invention also relates to a method for identifying new markers that are diagnostic of a disease or disorder associated with aberrant GSK-3? expression and/or activity. Furthermore, the present invention relates to methods of identifying and producing candidate compounds for the treatment of a disease or disorder associated with aberrant GSK-3? expression and/or activity.Type: ApplicationFiled: May 6, 2005Publication date: February 12, 2009Inventors: Peter Robert Schofield, John Bing Jee Kwok
-
Publication number: 20090041863Abstract: The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.Type: ApplicationFiled: September 19, 2005Publication date: February 12, 2009Inventor: Dennis E. Hallahan
-
Publication number: 20090041857Abstract: A herbal topical composition is used having complexed trace minerals capable of effectively reducing bone and joint inflammation by inhibiting inflammation pathways and in particular COX-2. The herbal composition having trace elements in a topical carrier reduces inflammation while avoiding the side effects associated with traditional drug therapy.Type: ApplicationFiled: August 7, 2007Publication date: February 12, 2009Applicant: Nabob RxInventors: Robert L. Gross, Nancy L. Leventoff
-
Publication number: 20090028904Abstract: A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.Type: ApplicationFiled: April 23, 2008Publication date: January 29, 2009Applicant: BioDelivery Sciences International, Inc.Inventors: Leila Zarif, Tuo Jin, Ignacio Segarra, Raphael J. Mannino
-
Publication number: 20090028961Abstract: The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms are applied by spraying, rubbing or immersion of contaminated surfaces thereby destroying, solubilizing inactivating and removing proteins and nucleic acids. In that way also microorganisms are killed with high efficiency and at the same time all genetic information is inactivated.Type: ApplicationFiled: May 2, 2006Publication date: January 29, 2009Applicant: MULTIBIND BIOTEC GMBHInventors: Thomas Lisowsky, Karlheinz Esser, Richard Lisowsky
-
Publication number: 20090017136Abstract: The formulation provides for the treatment and prevention of fibromyalgia, depression and other muscle and nervous system disorders. The formulation combines Coenzyme Q10, vitamin B1, 5-Hydroxytryptophan, magnesium, Vitamin D, Vitamin C, Selenium and Zinc. Each component has an effect on its own combined with a synergistic effect with other components.Type: ApplicationFiled: July 10, 2007Publication date: January 15, 2009Inventor: Wayne Gorsek
-
Publication number: 20090017047Abstract: Disclosed is a preparation for preventing and treating stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders, to be used by people suffering from actinic dermatitis, against sunburn, as a regenerative agent for damaged cells/cell systems, and for the well-being of humans and animals. Also disclosed are methods for isolating cell components from Aloe barbadensis miller, producing energized/magnetized microparticles and nanoparticles, and using cell components. Previously known substances that arm used for the indications mentioned above are expensive to produce or have insufficient effective properties. Preparations containing glycine, especially in a gel formulation, are easy to produce while being surprisingly advantageous for the most various applications.Type: ApplicationFiled: June 10, 2005Publication date: January 15, 2009Inventor: Egon Tech
-
Patent number: 7476660Abstract: The present invention relates to a composition for organ preservation, comprising an inulin type fructan as an active ingredient. The composition for organ preservation can suppress the hypofunction of an organ and damage to a histological structure and can improve the state of preservation of the organ in the course of organ transplantation and the like.Type: GrantFiled: March 28, 2003Date of Patent: January 13, 2009Assignee: Meiji Seika Kaisha, Ltd.Inventors: Yoshihiko Masaki, Kazunari Yoshida, Tadao Endo, Hirofumi Nakamura, Yasuhito Tashiro
-
Inhibitor of PI3 kinase-dependent inflammatory cytokine synthesis and method for inhibiting the same
Publication number: 20080317875Abstract: The present invention provides a novel inhibitor for inhibiting synthesis of a PI3 kinase-dependent inflammatory cytokine in vivo in a vertebrate and a method for inhibiting the same. More particularly, the present invention provides a suppressor for suppressing a cell-mediated immune response and a method for suppressing the same, as well as an activator for activating a humoral immune response and a method for activating the same. In the present invention, by administering Li ion to a living body to inhibit synthesis of an inflammatory cytokine, a cell-mediated immune responses can be suppressed, and immune-mediated inflammatory disorders (IMIDs) can be treated.Type: ApplicationFiled: July 9, 2007Publication date: December 25, 2008Inventors: Shigeo Koyasu, Masashi Ohtani, Chihiro Sasakaw, Sei Yoshida -
Publication number: 20080317800Abstract: The present invention relates to a biocidal composition, a method for its production and the use of the biocidal composition.Type: ApplicationFiled: February 15, 2007Publication date: December 25, 2008Inventor: Djamschid Amirzadeh-Asl
-
Publication number: 20080317876Abstract: The present invention describes the use of the magnetic magnesium isotope 25Mg2+ for the manufacture of a medicament for treating hypoxia. Furthermore, the present invention provides a medicament for treating hypoxia comprising the magnetic magnesium isotope 25Mg2+ and a porphylleren compound according to formula (I) wherein the residues A1, A2, A3, and A4 independently are a group containing 1 to 40 carbon atoms and at least one carboxylic group, the residues R, R? and R? independently are hydrogen or a group containing 1 to 80 carbon atoms, M is 2 H or an element capable of complexing with pyrrole nitrogen atom and L is a linking group and B is a fullerene residue.Type: ApplicationFiled: May 19, 2008Publication date: December 25, 2008Inventors: Saeed Sarkar, Seyed Mahdi Rezayat, Anatoly Leonidovich Buchachenko, Dmitry Anatolevich Kuznetsov, Marina Alexeyevna Orlova, Marina Abramovna Yurovskaya, Igor Viktorovich Trushkov
-
Publication number: 20080311227Abstract: The fungi-preventative-over-time characteristic of a fungicidal metal hydrochlorite, as distinguished from the fungi-removal characteristic thereof, is greatly enhanced by adding thereto only small amounts of active fungicidal compounds selected from the group consisting of lithium hydrochlorite and iodopropynyl butyl carbamate.Type: ApplicationFiled: June 18, 2007Publication date: December 18, 2008Inventors: Meghan Gressler, Ernest Bernarducci
-
Publication number: 20080299197Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: June 18, 2008Publication date: December 4, 2008Applicant: OSMOTICA CORP.Inventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Patent number: 7455859Abstract: Liquid and solid bromine-containing compositions are described. A liquid mixed halogen composition is also described. The highly concentrated liquid compositions and the high-activity solid compositions have excellent physical and chemical stability. The compositions are effective biocides in water treatment. Methods of preparing the compositions are also disclosed. These include combining a bromine compound in the oxidation state of ?1 with hydrogen peroxide and a complexing agent followed by the addition of an alkaline source. The methods may further include the use of a solid organic or solid inorganic halogenating agent, conducting a solid-liquid separation, and adding an alkaline source.Type: GrantFiled: January 27, 2006Date of Patent: November 25, 2008Assignee: Enviro Tech Chemical Services, Inc.Inventors: Jonathan N. Howarth, Michael S. Harvey
-
Publication number: 20080286258Abstract: The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders.Type: ApplicationFiled: March 23, 2007Publication date: November 20, 2008Inventors: Irene Eijgendaal, Gerrit Klein, Maria J.L. Terhorst-Van Amstel, Klaas Zwier, Nico Bruins, Hendrikus T. Rigter, Erik Gout, Caroline Boon, Michiel H. De Vries, Dorte Malling, Anneke Winsemius, Sangeeta Raje, Ellen Bech Christensen, Jeff Paul
-
Publication number: 20080286261Abstract: The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride. Methods of inhibiting hair growth are also provided.Type: ApplicationFiled: February 2, 2007Publication date: November 20, 2008Inventors: Bruce A. Morgan, Jiro Kishimoto, Robert Burgeson
-
Patent number: 7445801Abstract: Stable single bicarbonate-based solutions are provided. The bicarbonate-based single solution of the present invention includes at least calcium and bicarbonate and is stored or packaged in a sterile manner within a container with a gas barrier. The single solutions of the present invention can remain stable for three months or more. In this regard, the stable and single bicarbonate-based solutions of the present invention can be readily and effectively used during medical therapy, such as dialysis therapy.Type: GrantFiled: June 7, 2002Date of Patent: November 4, 2008Assignees: Baxter International Inc., Baxter Healthcare S.AInventors: Dirk Faict, Annick Duponchelle, Michel Taminne, Patrick Balteau, Francesco Peluso
-
Publication number: 20080268043Abstract: The invention relates to a formulation for the treatment of acute manic episodes associated with Bipolar I Disorder comprising an antipsychotic agent selected from the group consisting of: a dibenzothiazepine derivative; lithium; and divalproex. The formulation comprises a first component which comprises a first population the antipsychotic agent and at least one subsequent component which comprises a subsequent population of the antipsychotic agent and which allows for the modified release of the agent. The combination of the first and the subsequent components in operation deliver the antipsychotic agent in a pulsed or controlled manner over a period of up to twenty-four hours.Type: ApplicationFiled: January 26, 2006Publication date: October 30, 2008Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Scott A Jenkins, Gary Liversidge
-
Publication number: 20080260716Abstract: Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A log (6) reduction in Mycobacterium terrae is achieved on the surface in less than 10 minutes. The temperature may be produced by a physical chaotrope, a chemical chaotrope (such as) boron or a boron compound or complex or a combination of chaotropic agents. Sequestering agents and enzymes maybe added.Type: ApplicationFiled: July 5, 2005Publication date: October 23, 2008Applicant: Nanosonics Pty LimitedInventors: Steven Kritzler, Alex Sava
-
Publication number: 20080260708Abstract: Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself.Type: ApplicationFiled: April 19, 2007Publication date: October 23, 2008Inventor: Mickey A. Hall
-
Patent number: 7435380Abstract: A pseudo-plastic or thixotropic carrier having anti-malodorous components dissolved or suspended therein is sprayed on the internal surfaces of an ostomy bag or pouch. The viscoelastic properties of the carrier allow the composition to be conveniently dispensed from a spray bottle into the ostomy bag and retained on the inner walls thereof without being displaced therefrom by incoming waste during use of the ostomy bag. This allows the composition to continue to deodorize the ostomy bag headspace even after waste material begins to fill the bag.Type: GrantFiled: September 30, 2002Date of Patent: October 14, 2008Assignee: Church & Dwight Co., Inc.Inventor: Anthony E. Winston
-
Publication number: 20080248137Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.Type: ApplicationFiled: March 24, 2008Publication date: October 9, 2008Inventors: Guosong Liu, Fei Mao
-
Patent number: 7431945Abstract: The invention relates to an allergen remover composition containing component (a): an organic compound forming an azeotropic mixture with water and having an azeotropic point of lower than 100° C. with water at 1013.25 hPa, component (b): a component which upon evaporation of a liquid component in the allergen remover, forms a solid containing a compound represented by the following general formula (1) or component (b?): a combination of potassium ion, sodium ion and sulfate ion at a potassium ion/sodium ion molar ratio of from 2/8 to 9/1 and component (c): water. KxNay(SO4)2 ??(1) wherein x is a number of 0.8 to 3.6, y is a number of 0.4 to 3.2, and x+y is 4.Type: GrantFiled: November 9, 2004Date of Patent: October 7, 2008Assignee: Kao CorporationInventors: Takeshi Ban, Satoshi Nagai, Katsuyuki Takano, Masahiro Suzuki, Michio Yokosuka
-
Publication number: 20080241273Abstract: A dietary supplement and herbal formula and treatment methodology for humans and animals, having as its primary ingredient mastic gum extract, for the support, increase and production, function, and/or treatment of the kidneys.Type: ApplicationFiled: May 7, 2008Publication date: October 2, 2008Applicant: INTACT ENTERPRISES, INC.Inventor: Joseph Scivoletto
-
Publication number: 20080226744Abstract: A composition including a unique combination of fruits, vegetables, herbs, and optionally vitamins, minerals and specialty ingredients. The composition can include a fruit ingredient, a vegetable ingredient and an herbal ingredient, wherein the fruit ingredient is at least one of pomegranate and citrus bioflavonoids, wherein the vegetable ingredient, is at least one of asparagus, lutein, lycopene and watercress, and wherein the herbal ingredient is at least one of basil, oregano and rosemary. The composition can be administered to subjects to correct a dietary deficiency of phytochemicals and other nutrients, improve plasma concentrations of antioxidant nutrients, and increase the activity of genetic mechanisms for DNA repair and stability.Type: ApplicationFiled: March 31, 2008Publication date: September 18, 2008Applicant: ACCESS BUSINESS GROUP INTERNATIONAL LLCInventors: Ruo G. HUANG, Stephen R. MISSLER, Marc J.P. LEMAY, Edward S. KAHLER, Donald J. PUSATERI, Haeri ROH-SCHMIDT, Shyam RAMAKRISHNAN
-
Publication number: 20080226752Abstract: The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.Type: ApplicationFiled: March 21, 2008Publication date: September 18, 2008Applicant: NITROMED, INC.Inventors: Jay N. COHN, Peter CARSON
-
Publication number: 20080227642Abstract: The present invention generally relates to salts of abscisic acid analogs, aqueous liquid compositions containing salts of analogs of abscisic acid and methods of their preparation for agricultural use.Type: ApplicationFiled: January 30, 2008Publication date: September 18, 2008Inventors: Daniel F. Heiman, Bala Devisetty, Peter D. Petracek, Xiaozhong Liu, John Lopez, Derek D. Woolard, Yueh Wang, Gregory D. Venburg, Prem Warrior
-
Publication number: 20080220091Abstract: Reactive oxygen species associated with a wound are modulated through treatment of the wound with a solution of metal ions selected from the group consisting of potassium ions, zinc ions, calcium ions and rubidium ions, at a pH of between about 5 and about 7. Preferably, citric acid is employed to adjust the pH of the solution. Application of the extract to a wound exhibiting superoxide anions has been found to be effective in the treatment of these wounds through the reduction of the level of superoxide anions. Moreover, treatment of partial thickness excision wounds as well as contact burn wounds with the present composition has been found to improve epithelialization of these wounds. In addition to the antioxidant activity of the present invention, treatment of the wound employing the present composition produces inhibitory effects on ROS production by human PMNs and on human complement activation, and therefore, is further beneficial in chronic wound management.Type: ApplicationFiled: January 7, 2008Publication date: September 11, 2008Inventors: Stephen H. Monroe, Matthias Johannes Hoekstra, Albertus Justus Johannes Van Den Berg
-
Publication number: 20080213395Abstract: A method for the treatment and/or prophylaxis of disorders of the gastrointestinal system, other disorders selected from post exercise recovery, heat stress, vasovagal states, sleep disorders and fluid loss, and for the maintenance of blood sugar level homeostasis, comprising orally administering to said patient an admixture of vitamins and minerals formulated to have a pH greater than or equal to 5.0 in aqueous solution.Type: ApplicationFiled: October 14, 2005Publication date: September 4, 2008Applicant: ADVENTURES PLUS PTY LTDInventor: Mark Tuffley
-
Publication number: 20080213401Abstract: The invention relates to compositions for supporting healthy memory and optimizing mental energy and methods for improving, preventing, and treating mental disorders or deterioration. The compositions of the invention can be formulated as nutritional or dietary supplements.Type: ApplicationFiled: February 7, 2008Publication date: September 4, 2008Inventor: Kyl L. Smith
-
Patent number: 7419680Abstract: Compositions useful in the prevention and treatment of osteoporosis and for bone and fracture repair. Slow-releasing calcium phosphate-based materials are disclosed, incorporating Mg, Zn, F and carbonate, which will promote bone formation and inhibit bone resorption and thus be agents for the cited uses.Type: GrantFiled: September 28, 2004Date of Patent: September 2, 2008Assignee: New York UniversityInventor: Racquel Z. LeGeros
-
Publication number: 20080206359Abstract: An effective formulation for the treatment and prevention of pseudofolliculitis barbae, commonly called razor bumps, and the skin irritation associated with the condition. The treat formulation can be used as the last step in a multi-step shaving system consisting of a shaving gel, aftershave balm and the aforementioned treat. The treat can also be used as a standalone product and is formulated to treat and prevent shaving symptoms day and night.Type: ApplicationFiled: February 23, 2007Publication date: August 28, 2008Inventor: Nikita Wilson
-
Publication number: 20080187603Abstract: The present invention describes a novel antimicrobial ion delivery system (IDS) article, methods of making the article, and its applications in cleaning dentures and dentistry equipment. The novel IDS entails a source of oligodynamic metal ions embedded in a matrix that allows for the release of metal ions in water at concentrations that are biocidals and prevent biofilm formation. The preferred IDS contains particles made of metallic alloys and bound to a matrix that ensures the controlled release of ions in water. The novel IDS is safe for use in humans and it is environment friendly and biodegradable.Type: ApplicationFiled: October 6, 2007Publication date: August 7, 2008Applicant: Quartek CorporationInventor: Reyad I. Sawafta
-
Publication number: 20080187605Abstract: By disrupting a natural process used by developing mammalian brains to prune and delete surplus neurons, surgical anesthetics and other drugs that suppress brain activity in fetuses and infants can trigger permanent pathological brain damage. That type of damage can be prevented by drug interventions that block one or more “upstream” events that otherwise would lead to the release of “Cytochrome C”, a messenger molecule that triggers apoptosis (programmed cell death) among immature neurons. Lithium is a potent protective agent that can be coadministered along with ketamine or other NMDA-acting or GABA-acting anesthetics and anticonvulsants. Xenon gas triggers only mild damage, and can enable improved anesthesia when combined with other drugs. Other protective drugs (also called safener drugs), and treatments that can prevent or minimize fetal alcohol syndrome, also are disclosed.Type: ApplicationFiled: February 2, 2007Publication date: August 7, 2008Inventor: John W. Olney
-
Patent number: 7404967Abstract: Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical formulation vehicle, and methods of using these formulations to inhibit skin irritation, are disclosed.Type: GrantFiled: November 21, 2001Date of Patent: July 29, 2008Assignee: Cosmederm, Inc.Inventors: Gary S. Hahn, David O. Thueson
-
Publication number: 20080175904Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.Type: ApplicationFiled: May 24, 2005Publication date: July 24, 2008Applicant: Nycomed Pharma ASInventors: Jacob Mathiesen, Carsten M. Nielsen, Peder M. Olsen, Poul E. Bertelsen
-
Publication number: 20080161746Abstract: This invention provides new and novel devices and methods for administering lithium (Li) ions to a mammalian subject, especially the delivery of lithium (Li) ions to a body component for example across a body or tissue surface such as skin or a mucosal membrane, or for delivery of lithium ions directly to bodily fluids in a controllable and reproducible manner. In certain embodiments the device comprises a donor electrode that is a donor of a lithium ion; a protective architecture that is ionically conductive to the lithium ion, configured for application to a skin surface and positioned to isolate said donor electrode from the skin surface; and a counter electrode assembly configured for application to a skin surface, where said counter electrode assembly comprises a counter electrode operably coupled to said donor electrode.Type: ApplicationFiled: November 28, 2007Publication date: July 3, 2008Applicant: POLYPLUS BATTERY COMPANYInventors: Steven J. Visco, Yevgeniy S. Nimon
-
Publication number: 20080145390Abstract: Method and article for providing a rapid, broad spectrum bacterial control, and a rapid and persistent antiviral control on an inanimate surface is disclosed. In the method, a compound or composition capable of lowering surface pH to less than about 4 is applied to the surface, and preferably is allowed to remain on the surface, and the nonvolatile components of the composition can form a barrier film or layer on a treated surface.Type: ApplicationFiled: June 4, 2007Publication date: June 19, 2008Applicant: THE DIAL CORPORATIONInventors: Timothy J. Taylor, Harry E. Towner, Janice L. Fuls, Bruce R. Cox, George E. Fischler, Priscilla S. Fox, Nancy D. Rodgers, James Dalton, Daniel E. Pedersen, John J. Rolando, Richard K. Staub
-
Publication number: 20080131527Abstract: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional management alternatives (such as suturing and/or administration of injected or systemic analgesia) are impractical, unaffordable or otherwise unavailable.Type: ApplicationFiled: September 17, 2007Publication date: June 5, 2008Applicant: ANIMAL ETHICS PTY LTDInventors: Meredith SHEIL, Allan GIFFARD, Charles Robert OLSSON
-
Publication number: 20080131504Abstract: The present invention is directed to a novel short term slow release drug delivery system, preferably for solid oral dosage forms of water-soluble, alkaline salts of alkali metals and alkaline earth metals comprising polyvinylpyrrolidone and CPAA and preferably a wax component.Type: ApplicationFiled: December 1, 2006Publication date: June 5, 2008Applicant: Mission Pharmacal Co.Inventors: Neill B. Walsdorf, Sr., Jon C. Taylor, Feng Zhang, Francis K. Sherwood, John J. Koleng
-
Patent number: 7378111Abstract: Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (A?) peptides, which are now believed to be the principal cause of Alzheimer's disease, thereby providing methods useful for the prevention, inhibition or reversal of the disease. Also provided are methods of using agents that specifically target the ? isoform of GSK-3, which is responsible for APP processing, making such selective GSK-3?-specific inhibitors especially useful in the treatment, prevention, and possible reversal of Alzheimer's disease. Further provided are kits and screening methods associated with the present methods.Type: GrantFiled: February 19, 2003Date of Patent: May 27, 2008Assignee: The Trustees of the University of PennsylvaniaInventors: Christopher J. Phiel, Christina A. Wilson, Virginia M-Y. Lee, Peter S. Klein
-
Publication number: 20080118579Abstract: The invention relates to a medical device comprising non-sintered bioactive glass particles or fibres having a diameter in the range 5-100 ?m, bioactive glass comprising SiO2, Na2O, CaO, K2O, MgO, B2O3 and P2O5, wherein the amount of SiO2 is 50-65 wt-% of the final total weight, Na2O is 5-26 wt-% of the final total weight, CaO is 10-25 wt-% of the final total weight, K2O is 0-15 wt-% of the final total weight, MgO is 0-6 wt-% of the final total weight, B2O3 is 0-4 wt-% of the final total weight, and P2O5 is 0-4 wt-% of the final total weight, provided that the total amount of Na2O and K2O is 10-30 wt-% of the final total weight The device is essentially drug free. The invention also relates to the use of said composition for treating lesions associated with compromised or poor vascularisation and for preventing avascular fibrosis.Type: ApplicationFiled: November 2, 2005Publication date: May 22, 2008Applicant: VIVOXID OYInventors: Hannu Jarvelainen, Matti Laato, Jukka Salonen, Erik Vedel
-
Publication number: 20080075710Abstract: An herbal composition is adapted to treat hangovers. In one embodiment, the herbal composition comprises potassium, thiamin (vitamin B-1), magnesium, silymarin and N-acetyl-L-cysteine (acetylcysteine), or any pharmaceutically acceptable salts thereof. In a method of treating hangovers, an herbal composition is provided that comprises potassium, thiamin, magnesium, silymarin and N-acetyl-L-cysteine. The herbal composition is placed in the body so as to alleviate or reduce the effects of a hangover.Type: ApplicationFiled: September 11, 2007Publication date: March 27, 2008Inventors: Erik T. Cornett, Gerad A. Harsy
-
Patent number: 7345029Abstract: The present invention relates to a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. The avoidance of a glucose-like degradation as well as hydrolysis during sterilization and storage while maintaining a neutral mixture pH is achieved according to the invention by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further relates to a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.Type: GrantFiled: April 18, 2003Date of Patent: March 18, 2008Assignee: Fresenius Medical Care Deutschland GmbHInventor: Thomas Zimmeck
-
Publication number: 20080057139Abstract: The skin-care water, which is able to safely improve skin health conditions, such as dry skin, contains water from which polyvalent cations are removed and to which sodium ions are added, and may contain fragrant materials according to need. When the skin-care water is applied to skin, for example, by means of taking a bath, it improves moisture retention of skin, moisture content of skin, elasticity, texture density and the like without providing side effects, as is often not the case when a skin-care water containing chemical substances is used. Accordingly, the skin-care water is useful as a moisturizing agent for skin, and an improving agent for dry skin, itchy feeling, skin scale and atopic dermatitis.Type: ApplicationFiled: August 27, 2007Publication date: March 6, 2008Inventors: Yuji Yoshinari, Masaki Takai, Makoto Hatori